NEXLETOL and NEXLIZET are indicated as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use: The effect of NEXLETOL and NEXLIZET on cardiovascular morbidity and mortality has not been determined.
AACE=American Association of Clinical Endocrinology; ACE=American College of Endocrinology; LDL-C=low-density lipoprotein cholesterol.
References: 1. Handelsman Y, Jellinger P, Guerin C, et al. AACE/ACE management of dyslipidemia and prevention of cardiovascular disease algorithm. Presented at: AACE Innovation in Cardiometabolic Clinical Conference. October 2020. 2. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 3. NEXLETOL. Prescribing information. ESPERION Therapeutics, Inc.; 2020. 4. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 2020.